NYSEArca - Delayed Quote
USD
State Street Consumer Staples Select Sector SPDR ETF (XLP)
84.58
-0.68
(-0.80%)
At close: September 4 at 4:00:00 PM EDT
85.37
+0.79
(+0.93%)
After hours: September 4 at 7:55:43 PM EDT
Trade XLP on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for XLP
- Previous Close
85.26 - Open
84.82 - Bid 84.56 x 350000
- Ask 84.80 x 440000
- Day's Range
84.54 - 85.29 - 52 Week Range
75.16 - 90.14 - Volume
9,823,945 - Avg. Volume
10,739,573 - Net Assets 14.52B
- NAV 85.24
- PE Ratio (TTM) 25.02
- Yield 2.59%
- YTD Daily Total Return 11.14%
- Beta (5Y Monthly) 0.49
- Expense Ratio (net) 0.08%
Performance Overview
View MoreTrailing returns as of 9/3/2026. Category is Consumer Defensive.
People Also Watch
XLY
State Street Consumer Discretionary Select Sector SPDR ETF
114.91 -1.33%
XLI
State Street Industrial Select Sector SPDR ETF
175.27 +0.41%
XLB
State Street Materials Select Sector SPDR ETF
52.44 -0.34%
XLU
State Street Utilities Select Sector SPDR ETF
43.08 +0.12%
XLV
State Street Health Care Select Sector SPDR ETF
171.45 -1.04%
Holdings
View MoreTop 10 Holdings (61.74% of Total Assets)
Sector Weightings
Sector
XLP
Consumer Defensive
98.22%
Consumer Cyclical
1.78%
Real Estate
0.00%
Basic Materials
0.00%
Technology
0.00%
Communication Services
0.00%
Financial Services
0.00%
Utilities
0.00%
Industrials
0.00%
Energy
0.00%
Healthcare
0.00%
Recent News
View More
Research Reports
View More-
Biogen Is Repositioning Its Portfolio To Partly Offset Ongoing Revenue Declines
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice Target -
Biogen Earnings: Growth Portfolio Outpaces Legacy Portfolio Erosion; Guidance Raised
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice Target -
Biogen and Ionis: Mixed Phase 2 Data for Alzheimer's Disease Candidate
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice Target -
Biogen and Ionis: Mixed Phase 2 Data for Alzheimer's Disease Candidate
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
RatingPrice Target
Related Tickers
PSI
Invesco Semiconductors ETF
136.00 +4.86%
FTXL
First Trust Nasdaq Semiconductor ETF
227.85 +3.60%
SOXX
iShares Semiconductor ETF
519.86 +3.52%
AIA
iShares Asia 50 ETF
143.74 +3.14%
XSD
State Street SPDR S&P Semiconductor ETF
491.45 +2.70%
SMH
VanEck Semiconductor ETF
567.01 +2.61%
FPA
First Trust Asia Pacific Ex-Japan AlphaDEX Fund
51.03 +2.19%
EMXC
iShares MSCI Emerging Markets ex China ETF
101.12 +1.88%
EWT
iShares MSCI Taiwan ETF
112.18 +1.86%
MTUM
iShares MSCI USA Momentum Factor ETF
304.86 +1.82%
CSD
Invesco S&P Spin-Off ETF
132.66 +1.77%
FLAX
Franklin FTSE Asia ex Japan ETF
37.37 +1.71%
FLTW
Franklin FTSE Taiwan ETF
107.88 +1.69%
EMGF
iShares Emerging Markets Equity Factor ETF
73.67 +1.63%
KNCT
Invesco Next Gen Connectivity E
198.20 +1.63%
SPMO
Invesco S&P 500 Momentum ETF
149.72 +1.57%
